Veranex Announces Investment From Summit Partners to Form Comprehensive Concept-to-Commercialization Medtech Services Company

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.

Veranex today announced the formation of the first concept-to-commercialization global service provider dedicated to the medtech industry. Formed in partnership with global growth investor Summit Partners, the Veranex platform is designed to provide the global medical technology industry with access to real-time integrated strategy across the product life cycle.

As the first phase in building this global entity, Veranex has acquired three complementary solution providers: Ximedica, Quartesian, and Boston Healthcare Associates. By bringing these companies together, Veranex combines the industry’s key pillars of design and engineering, regulatory, clinical, and market access into a single-source solution.

“We are thrilled to partner with Pat Donnelly, David Dockhorn, and the rest of the Veranex management team to help them execute on their vision of building a fully integrated design, development, and commercialization solution for the medtech industry,” said Darren Black, managing director at Summit Partners. “This team has a demonstrated history of building leading clinical research businesses and we look forward to supporting the Veranex platform through both organic and acquisition-driven growth.”

“Veranex is designed to bring a single-partner medical technology solution to our industry for the first time,” said David Dockhorn, CEO of Veranex. “Veranex is a comprehensive, international one-stop medtech service provider, and we plan to continue building the platform organically and through acquisition in order to enhance our ability to help clients control costs and accelerate speed to market, all while mitigating development risk and delivering rapid global market viability assessments.”

With the extensive product development experience of the three companies — now merged as Veranex — customers have access to real-time integrated strategy driven by industry-leading expertise and underpinned by advanced technologies across the medtech development life cycle. The combined company brings deep experience in the areas of device, in vitro diagnostics, companion diagnostics, digital health, and combination products/drug delivery. Therapeutic areas of focus include cardiovascular, orthopedic, women’s health, wound care, ophthalmology, and gastrointestinal.

“We saw an opportunity to address current market challenges and the lack of a full-scale global service provider by combining this solution set of three leading companies to work in a complementary way and redefine what it means to be a comprehensive medtech service provider,” said Veranex Executive Chairman Pat Donnelly. “We believe the Veranex platform will serve to unify the medtech development process, helping clients create synergies across every stage of the development spectrum in ways not previously available in the market.”

Veranex is designed to deliver market access and strategic positioning expertise — globally and across complex and emerging markets — to drive early health economics and outcomes research (HEOR) decisions that optimize commercialization strategies and improve market adoption. The company’s leadership brings a wealth of well-established global regulatory guidance experience, strong relationships with the FDA, and a demonstrated track record of successful approvals.

Veranex CEO David Dockhorn has 32 years of life sciences operating experience in various leadership roles. Most recently, he was executive vice president and chief compliance officer at PRA Health Sciences (NASDAQ: PRAH). Veranex Executive Chairman Pat Donnelly has been a pharma services founder and executive for over 28 years. He was one of the founders of PRA International (now PRA Health Sciences) where he served as CEO and president. Pat was formerly chairman and CEO of both Advarra and Aptiv Solutions as well as having served on the board of directors for Celerion, ProPharma Group, MedGenesis Therapeutix, and Rediscovery Life Sciences.

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.